1. Scrip
  2. >>Business
  3. >>Deals

Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer

$11.5bn Acquisition Values Firm At A 34%-38% Premium

 
• By Mandy Jackson

Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.

Hand turns a dice and changes the expression "bad deal" to "good deal"
Three investors said they will not sell their Acceleron shares to Merck • Source: Alamy

Three investment firms with significant holdings in Acceleron Pharma, Inc. have come forward to encourage the company’s other shareholders not to tender their shares in Merck & Co., Inc.’s $11.5bn deal to buy the company. Avoro Capital, Holocene Advisors and Darwin Global Management Limited say the acquisition’s $180-per-share price significantly undervalues Acceleron as it awaits Phase III data for its potentially disease-modifying pulmonary arterial hypertension (PAH) drug candidate sotatercept.

Merck highlighted sotatercept as a drug with blockbuster sales potential that could meaningfully expand the company’s cardiovascular disease portfolio, when...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

 
• By Joseph Haas, Sushmita Panda, Xu Hu, Vibha Ravi, and Manas Mishra

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer

 
• By Andy Smith

The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.